Sensars is a medtech start-up developing implantable neuroprosthetics for diabetic neuropathy complications such as diabetic foot ulcers, amputation and falls prevention and neuropathic pain treatment. Our flagship system, SENSY, restores natural foot sensation in patients with diabetes, sensory loss, or prosthetic limbs using neuromodulation and AI-driven gait analysis. By restoring sensation, SENSY prevents ulcers, amputations, falls, and chronic pain, improving patient survival and independence. Backed by FDA Breakthrough Device Designation, strong IP, and peer-reviewed clinical data, Sensars addresses a massive unmet need in diabetic foot care.

News

10.08.2018 Sleepiz and nanoleq win ? 50,000 each (startupticker.ch)

Milestones/News

31.07.2025 CHF 600k; Added CFO; Expanded advisory board; Completed implantable product;
20.01.2024 1.1M eur round of grants + convertible loan
22.10.2018 EIT headstart 2018
16.01.2017 Pilot clinical trial with SENSY
26.07.2016 Support from SPECO
10.06.2016 top 25 Venture
01.07.2014 INNOGRANT 2014
12.06.2014 SensArs Incorporation